Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556642 · ClinicalTrials.gov registry record
Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
A clinical trial of Relapsed Hepatoblastoma and Refractory Hepatoblastoma, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05556642: Recruiting study of Relapsed Hepatoblastoma and Refractory Hepatoblastoma, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT05556642 is a study of Relapsed Hepatoblastoma and Refractory Hepatoblastoma that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05556642, a study of Relapsed Hepatoblastoma and Refractory Hepatoblastoma, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with rrHBL, prospectively. Cases are identified through: 1. Existing clinical and/or cancer registry databases 2. Referrals from clinicians, surgeons, or pathologists 3. Families initiating contact with Registry staff directly
Primary Outcome
To characterize rrHBL across all age groups with regards to demographics, presenting features, pathology, radiology, clinical course, treatments and response
Conditions Studied
Interventions
- OTHER Biospecimen collection
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2040-09-01 |
What NCT05556642 shows while recruiting
NCT05556642 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Relapsed Hepatoblastoma appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen collection is the first listed.
NCT05556642 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05556642 about?
NCT05556642 is a clinical study titled "Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative". There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registr...
What is the current status of trial NCT05556642?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-09-07. Estimated completion is 2040-09-01.
What conditions does trial NCT05556642 study?
This clinical trial studies the following conditions: Relapsed Hepatoblastoma, Refractory Hepatoblastoma.
What interventions are being tested in trial NCT05556642?
The interventions under investigation include: Biospecimen collection (OTHER).
Who is sponsoring clinical trial NCT05556642?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05556642 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI